News and Events

Learn more about us, our science and our journey here.

Blogs

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Events

Helex presented with the Outstanding Poster Award at ASGCT2024 for the abstract on our therapeutic intervention for Autosomal Dominant Polycystic Kidney Disease!

May 14, 2024

Helex to present 3 posters at ASGCT 2024 in Baltimore covering our CRISPR Cas9 therapeutic approach for Autosomal Dominant Polycystic Kidney Disease and our drug design technology's guideRNA design and safety assessment capabilities

May 3, 2024

Helex CEO, Poulami Chaudhuri, Ph D, interviewed by Inside Precision Medicine magazine on Helex's approach to using the 3D genome structure and epigenome to guide development of gene edited therapies

June 1, 2023

Press & publications

Helex Chief Growth Officer, Rohini Kalvakuntla, interviewed by Cure magazine on Helex's pioneering work in developing innovative therapies to combat genetic kidney diseases

Biotech startup Helex brings precision to gene editing

All the top 10 companies from IndieBio’s latest New York Cohort